Assessing Cardiovascular Drug Safety for Clinical Decision-Making

Nat Rev Cardiol. 2013 Jun;10(6):330-7. doi: 10.1038/nrcardio.2013.57. Epub 2013 Apr 16.

Abstract

Optimal therapeutic decision-making requires integration of patient-specific and therapy-specific information at the point of care, particularly when treating patients with complex cardiovascular conditions. The formidable task for the prescriber is to synthesize information about all therapeutic options and match the best treatment with the characteristics of the individual patient. Computerized decision support systems have been developed with the goal of integrating such information and presenting the acceptable therapeutic options on the basis of their effectiveness, often with limited consideration of their safety for a specific patient. Assessing the safety of therapies relative to each patient is difficult, and sometimes impossible, because the evidence required to make such an assessment is either imperfect or does not exist. In addition, many of the alerts sent to prescribers by decision-support systems are not perceived as credible, and 'alert fatigue' causes warnings to be ignored putting patients at risk of harm. The CredibleMeds.org and BrugadaDrugs.org websites are prototypes for evidence-based sources of safety information that rank drugs for their risk of a specific form of drug toxicity-in these cases, drug-induced arrhythmias. Broad incorporation of this type of information in electronic prescribing algorithms and clinical decision support could speed the evolution of safe personalized medicine.

Publication types

  • Review

MeSH terms

  • Adverse Drug Reaction Reporting Systems*
  • Animals
  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / therapeutic use*
  • Data Mining
  • Databases, Pharmaceutical
  • Decision Support Techniques*
  • Drug Interactions
  • Humans
  • Medication Errors / prevention & control*
  • Patient Safety
  • Patient Selection
  • Reminder Systems
  • Risk Assessment
  • Risk Factors
  • Systems Integration

Substances

  • Cardiovascular Agents